Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase

被引:16
|
作者
Lee, Jisun [1 ,2 ]
Choi, Kyu Jin [3 ]
Lim, Min Jin [1 ,2 ]
Hong, Feng [1 ,2 ]
Choi, Tae Gyu [1 ,2 ]
Tak, Eunyoung [1 ,2 ]
Lee, Seonmin [1 ,2 ]
Kim, Young-Joo [4 ]
Chang, Sung Goo [5 ]
Cho, Jin Man [6 ]
Ha, Joohun [1 ,2 ]
Kim, Sung Soo [1 ,2 ]
机构
[1] Kyung Hee Univ, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Dept Biochem & Mol Biol,Project BK21, Seoul 130701, South Korea
[2] Kyung Hee Univ, Sch Med, Inst Biomed Sci, Seoul 130701, South Korea
[3] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea
[4] Jeju Natl Univ, Dept Urol, Coll Med, Cheju 690756, South Korea
[5] Kyung Hee Univ, Sch Med, Dept Urol, Seoul 130701, South Korea
[6] Kyung Hee Univ, EW Neomed Ctr, Ctr Cardiovasc, Seoul 134090, South Korea
关键词
c-Ras; PI3K; muscle differentiation; PARTIAL FUNCTIONAL OVERLAP; KAPPA-B; SIGNAL-TRANSDUCTION; CYCLOPHILIN-A; ERK PATHWAY; ACTIVATION; KINASE; INSULIN; INHIBITION; PROTEIN;
D O I
10.1038/cr.2010.92
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oncogenic H-Ras G12V and its variants have been shown to inhibit muscle differentiation. However, the role of proto-oncogenic Ras (c-Ras) in muscle differentiation remains unclear. The active GTP-bound form of Ras has been known to associate with diverse effectors including Raf, phosphatidylinositol 3-kinase (PI3K), Ral-GDS, and other molecules to transmit downstream signals. We hypothesize that c-Ras may stimulate muscle differentiation by selectively activating PI3K, an important mediator for muscle differentiation. In our experiments, inhibition of c-Ras by farnesyltransferase inhibitors and a dominant negative form of H-Ras (Ras S17N) suppressed muscle differentiation. Consistently, individual knockdown of H-Ras, K-Ras, and N-Ras by siRNAs all blocked muscle differentiation. Interestingly, we found that c-Ras preferentially interacts with PI3K rather than its major binding partner c-Raf, during myogenic differentiation, with total c-Ras activity remaining unchanged. PI3K and its downstream myogenic pathway, the Nox2/NF-kappa B/inducible nitric oxide synthase (iNOS) pathway, were found to be suppressed by inhibition of c-Ras activity during differentiation. Furthermore, expression of a constitutively active form of PI3K completely rescued the differentiation block and reactivated the Nox2/NF-kappa B/iNOS pathway in c-Ras-inhibited cells. On the basis of our results, we conclude that contrary to oncogenic Ras, proto-oncogenic H-Ras, K-Ras, and N-Ras are directly involved in the promotion of muscle differentiation via PI3K and its downstream signaling pathways. In addition, PI3K pathway activation is associated with a concurrent suppression of the otherwise predominantly activated Raf/Mek/Erk pathway.
引用
收藏
页码:919 / 934
页数:16
相关论文
共 50 条
  • [11] Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients
    Malgorzata Banys-Paluchowski
    Karin Milde-Langosch
    Tanja Fehm
    Isabell Witzel
    Leticia Oliveira-Ferrer
    Barbara Schmalfeldt
    Volkmar Müller
    Breast Cancer Research and Treatment, 2020, 179 : 403 - 414
  • [12] Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex
    Keller, J. W.
    Haigis, K. M.
    Franklin, J. L.
    Whitehead, R. H.
    Jacks, T.
    Coffey, R. J.
    ONCOGENE, 2007, 26 (21) : 3051 - 3059
  • [13] Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
    Haigis, Kevin M.
    Kendall, Krystle R.
    Wang, Yufang
    Cheung, Ann
    Haigis, Marcia C.
    Glickman, Jonathan N.
    Niwa-Kawakita, Michiko
    Sweet-Cordero, Alejandro
    Sebolt-Leopold, Judith
    Shannon, Kevin M.
    Settleman, Jeffrey
    Giovannini, Marco
    Jacks, Tyler
    NATURE GENETICS, 2008, 40 (05) : 600 - 608
  • [14] Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex
    J W Keller
    K M Haigis
    J L Franklin
    R H Whitehead
    T Jacks
    R J Coffey
    Oncogene, 2007, 26 : 3051 - 3059
  • [15] Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients
    Banys-Paluchowski, Malgorzata
    Milde-Langosch, Karin
    Fehm, Tanja
    Witzel, Isabell
    Oliveira-Ferrer, Leticia
    Schmalfeldt, Barbara
    Mueller, Volkmar
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 403 - 414
  • [16] Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
    Kevin M Haigis
    Krystle R Kendall
    Yufang Wang
    Ann Cheung
    Marcia C Haigis
    Jonathan N Glickman
    Michiko Niwa-Kawakita
    Alejandro Sweet-Cordero
    Judith Sebolt-Leopold
    Kevin M Shannon
    Jeffrey Settleman
    Marco Giovannini
    Tyler Jacks
    Nature Genetics, 2008, 40 : 600 - 608
  • [17] IMMUNOHISTOCHEMICAL DETECTION OF THE H-RAS, K-RAS, AND N-RAS ONCOGENES IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    MCDONALD, JS
    JONES, H
    PAVELIC, ZP
    PAVELIC, LJ
    STAMBROOK, PJ
    GLUCKMAN, JL
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1994, 23 (08) : 342 - 346
  • [18] INFREQUENT INVOLVEMENT OF MUTATIONS ON NEUROFIBROMATOSIS TYPE-1, H-RAS, K-RAS AND N-RAS IN UROTHELIAL TUMORS
    UCHIDA, T
    WADA, C
    ISHIDA, H
    EGAWA, S
    AO, T
    YOKOYAMA, E
    KOSHIBA, K
    UROLOGIA INTERNATIONALIS, 1995, 55 (02) : 63 - 67
  • [19] Mutation and expression analysis of K-Ras, H-Ras, N-Ras and B-Raf oncogenes in Wilms tumors
    Dalpa, Efterpi
    Gourvas, Victor
    Soulitzis, Nikolaos
    Spandidos, Demetrios A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S93 - S93
  • [20] SERUM GROWTH-FACTORS UP-REGULATE H-RAS, K-RAS, AND N-RAS PROTOONCOGENES IN FIBROBLASTS
    QUINCOCES, AF
    LEON, J
    CELL GROWTH & DIFFERENTIATION, 1995, 6 (03): : 271 - 279